The technology will measure cancer-associated miRNAs using optical amplification with quantum dots and photonic crystals.
GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.
Given the high yield of miRNA markers they were able to isolate, the researchers believe the approach could be commercialized for routine cancer testing.
The Singapore-based firm has established a US subsidiary and named distributors to sell its products across Europe, the Middle East, and Asia.
The company, which is also developing a therapeutic for the liver disease, plans to pursue regulatory approval in the US and Europe.
Using array-based miRNA profiles for individuals treated for prostate cancer, researchers identified 37 miRNA with differential expression in cases with recurrence.
The French firm said that the funds will go toward international development and the marketing of the company's autoimmunity, allergy, and theranostic products.
The New York State Department of Health had previously provided conditional approval of the microRNA classifier for diagnosing indeterminate thyroid cancer cases.
After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly.
The collaborators are developing tests for rectal cancer based on microRNA and messenger RNA signatures.